Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Liposomal Irinotecan Combined With Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
NCT07570914Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in Colorectal cancer with liver metastases (CRLM), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
Colorectal cancer with liver metastases (CRLM)
Beyond the preview
Go deeper on NCT07570914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570914.